XERS vs LLY

For growth investors, Eli Lilly and Company (LLY) is the stronger pick with 44.

7% revenue growth year-over-year, versus 43. 7% for Xeris Biopharma Holdings, Inc. (XERS). Eli Lilly and Company (LLY) offers the better valuation at 43. 0x trailing P/E (28. 6x forward), making it the more compelling value choice. Analysts rate Xeris Biopharma Holdings, Inc. (XERS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Eli Lilly and Company (LLY) is the cheapest at 43.

0x versus Xeris Biopharma Holdings, Inc. at 1990. 6x. On forward P/E, Eli Lilly and Company is actually cheaper at 28. 6x.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +421.

4%, compared to +87. 9% for Xeris Biopharma Holdings, Inc. (XERS). Over 10 years, the gap is even starker: LLY returned +1272% versus XERS's -68. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Eli Lilly and Company (LLY) is the lower-risk stock at 0.

71β versus Xeris Biopharma Holdings, Inc. 's 1. 04β — meaning XERS is approximately 47% more volatile than LLY relative to the S&P 500. On balance sheet safety, Eli Lilly and Company (LLY) carries a lower debt/equity ratio of 160% versus 3% for Xeris Biopharma Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Eli Lilly and Company (LLY) is pulling ahead at 44.

7% versus 43. 7% for Xeris Biopharma Holdings, Inc. (XERS). On earnings-per-share growth, the picture is similar: Xeris Biopharma Holdings, Inc. grew EPS 100. 9% year-over-year, compared to 96. 0% for Eli Lilly and Company. Over a 3-year CAGR, XERS leads at 38. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus 0. 2% for Xeris Biopharma Holdings, Inc. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus 8. 5% for XERS. At the gross margin level — before operating expenses — LLY leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Eli Lilly and Company (LLY) trades at 28.

6x forward P/E versus 53. 1x for Xeris Biopharma Holdings, Inc. — 24. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for XERS: 41. 3% to $9. 00.

In this comparison, LLY (0.

6% yield) pays a dividend. XERS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

71), 0. 6% yield, +1272% 10Y return). Both have compounded well over 10 years (LLY: +1272%, XERS: -68. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

LLY pays a dividend while XERS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.